ClinicalTrials.Veeva

Menu

The Use of Low Molecular Weight Heparin in Traumatic Brain Injury

Hennepin Healthcare logo

Hennepin Healthcare

Status and phase

Completed
Phase 4

Conditions

Brain Injury
Venous Thrombosis

Treatments

Drug: Enoxaparin

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00170378
HSR #02-2113

Details and patient eligibility

About

To study the safety and efficacy of early administration of Low Molecular Weight Heparin to patients with traumatic brain injury.

Full description

Venous thromboembolic (VTE) prophylaxis in trauma patients is a critical clinical problem. Patients with traumatic brain injury usually have effective VTE prophylaxis withheld secondary to concerns of exacerbating intracranial hemorrhage. This study examines the safety and efficacy of early administration (within 24 hrs of admission) of low molecular weight heparin to this patient population with very high VTE risk.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Blunt traumatic brain injury (Marshall II-V)
  • Stable 6 hr. head CT
  • Stable hemoglobin

Exclusion criteria

  • Premorbid coagulopathy
  • Pregnancy
  • < 18 y.o.
  • Need for therapeutic anticoagulation
  • Heparin allergy

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems